Comparison of plasma and CSF biomarkers in predicting cognitive decline.

Andrew J AschenbrennerYan LiRachel L HensonKatherine VolluzJason HassenstabPhilip VergheseTim WestMatthew R MeyerKristopher M KirmessAnne M FaganChengjie XiongDavid HoltzmanJohn C MorrisRandall J BatemanSuzanne E Schindler

Published in: Annals of clinical and translational neurology (2022)

Both plasma and CSF measures of Aβ42/Aβ40 and NfL predicted cognitive decline. A clinical trial that enrolled individuals based on abnormal plasma Aβ42/Aβ40 and NfL levels would require only a marginally larger cohort than if CSF measures were used.

Keyphrases

cognitive decline
mild cognitive impairment
clinical trial
cerebrospinal fluid
randomized controlled trial
open label